Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Gaceta médica de México
On-line version ISSN 2696-1288Print version ISSN 0016-3813
Abstract
AVILA-CASTRO, David et al. Proposal for the management of COVID-19-associated coagulopathy in children. Gac. Méd. Méx [online]. 2020, vol.156, n.4, pp.340-347. Epub May 27, 2021. ISSN 2696-1288. https://doi.org/10.24875/gmm.m20000417.
SARS-CoV-2 infection (COVID-19) has become a pandemic with a high case fatality rate that mainly affects adults. Most severely ill adult patients develop a coagulopathy that was not described until recently, and which is currently considered a main cause of death. Everything indicates that a similar phenomenon also occurs in children with COVID-19. Anticoagulant treatment has become one of the therapeutic foundations for this infection; however, its implementation in children can be difficult since, until recently, it was not considered in the pediatric population. Evidence regarding the use of anticoagulants in COVID-19 is rapidly generated, changes constantly, it is often difficult to interpret, and can be contradictory. After an extensive review of the published literature, a proposal was generated that offers suggestions for anticoagulant treatment, considering available resources in Mexico.
Keywords : COVID-19; Coagulopathy; Pediatric population; Venous thromboembolic disease; Anticoagulants.